2025-04-02 - Analysis Report
## Johnson & Johnson (JNJ) Stock Performance Review

**0. Key Figures Summary:**

JNJ's cumulative return significantly lags behind the S&P 500 (VOO).  While JNJ shows a relatively stable performance with moderate risk, its recent price action suggests potential weakness.  Earnings remain relatively consistent, and financial health appears strong, although recent ROE fluctuates.


**1. Performance Comparison with S&P 500 (VOO):**

Johnson & Johnson is a multinational healthcare company that manufactures pharmaceuticals, medical devices, and consumer health products.

* **JNJ Cumulative Return:** 35.84%
* **VOO (S&P 500) Cumulative Return:** 89.83%
* **Return Difference:** -54.0%  (JNJ underperformed VOO by 54 percentage points).
* **Relative Divergence:** 29.7% (Indicates JNJ's underperformance is in the lower 30th percentile of historical divergence from VOO).

Alpha and Beta analysis reveals inconsistent performance relative to the market (VOO): While JNJ generally shows a Beta significantly higher than 1, indicating higher volatility than the market, Alpha is mostly positive (except for 2015-2017 and 2016-2018) showing periods of outperformance.  However, the recent negative CAGR (2021-2024) highlights recent underperformance.

**2. Recent Price Movement:**

* **Closing Price:** $165.84
* **Last Market Price:** $153.91 (Significant drop of $7.2) indicating a potentially sharp downward trend.
* **5-day Moving Average:** $163.08
* **20-day Moving Average:** $164.04
* **60-day Moving Average:** $155.87

The price is below all three moving averages, suggesting a bearish trend.  The significant drop in the last market price warrants further investigation into potential market impacting news.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.44 (Low to Medium Risk)
* **RSI:** 49.93 (Near neutral; neither overbought nor oversold)
* **PPO:** -0.24 (Negative, indicating bearish momentum)
* **Recent Relative Divergence:** +3.5 (Short-term upward trend, but potentially negated by recent price drop).
* **Expected Return:** -57.7% (This extremely negative expected return needs further clarification.  It's likely misstated or refers to a specific scenario not fully explained in the context provided).  The provided -57.7% expected return is alarming and requires further analysis to understand its basis.
* **Long-term (2+ years) Expected Excess Return vs. S&P 500:**  Cannot be reliably determined from the given data.  Long-term expectations require more comprehensive forecasting models considering various macroeconomic factors and JNJ's future prospects.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-10-23 | $1.12  | $22.47B       |
| 2024-07-25 | $1.95  | $22.45B       |
| 2024-05-01 | $1.35  | $21.38B       |
| 2024-02-16 | $1.68  | $21.39B       |
| 2023-10-27 | $10.32 | $21.35B       |

EPS shows significant volatility, with a large outlier in October 2023.  Revenue remains relatively stable. Further investigation is needed to explain the unusual EPS spike in Q4 2023 and the subsequent decrease.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2024-12-31 | $22.52B     | 68.35%        |
| 2024-09-30 | $22.47B     | 69.01%        |
| 2024-06-30 | $22.45B     | 69.40%        |
| 2024-03-31 | $21.38B     | 69.55%        |
| 2023-12-31 | $21.39B     | 68.23%        |

Revenue shows slight growth, while profit margins are consistently high and stable.


**Capital and Profitability:**

| Quarter    | Equity      | ROE           |
|------------|-------------|---------------|
| 2024-12-31 | $71.49B     | 4.80%         |
| 2024-09-30 | $70.16B     | 3.84%         |
| 2024-06-30 | $71.54B     | 6.55%         |
| 2024-03-31 | $70.02B     | 4.65%         |
| 2023-12-31 | $68.77B     | 5.89%         |

Equity fluctuates slightly, and ROE shows some variability, suggesting potential underlying financial factors affecting profitability.


**6. Overall Analysis:**

JNJ demonstrates a strong financial position with high and consistent profit margins. However, its recent stock performance significantly underperformed the S&P 500. The substantial price drop in the last market close and bearish technical indicators raise concerns.  The unusual EPS in Q4 2023 requires further investigation to determine its underlying cause. The -57.7% expected return is highly improbable and requires clarification.  Before making any investment decisions, further analysis is crucial to understand the reasons behind JNJ's underperformance and the volatility in EPS.  A thorough investigation into the recent price drop and the unusually high EPS value in Q4 2023 is essential.  The long-term outlook depends heavily on the resolution of these issues and the future trajectory of the healthcare industry.
